Intracranial response to capmatinib after progression on crizotinib in a patient with MET exon 14 skipping non-small cell lung cancer-a case report

Jóri B, Bundschuh O, Falk M, Heukamp LC, Kluge A, Tiemann M, et al. Intracranial response to capmatinib after progression on crizotinib in a patient with MET exon 14 skipping non-small cell lung cancer-a case report. Transl Lung Cancer Res 2024 Jul 30;13(7):1749-1755. doi:10.21037/tlcr-23-769. Epub 2024 Jul 15

Testing for deficient mismatch repair and microsatellite instability : A focused update

Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker Edmonston T, Dietmaier W, et al. Testing for deficient mismatch repair and microsatellite instability : A focused update. Pathologie (Heidelb.) 2023 Nov;44(Suppl 2):61-70. doi:10.1007/s00292-023-01208-2. Epub 2023 Oct 24

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, et al. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Curr Oncl 2023 Sep 27;30(10):8805-8814. doi:10.3390/curroncol30100635

Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets

Shakhpazyan N, Mikhaleva L, Bedzhanyan A, Giovea Z, Sadykhov N, Mikhalev A, et al. Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets. Biomedicines 2023 Aug 23;11(9):2361. doi: 10.3390/biomedicines11092361

Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis

Maslenkina K, Mikhaleva L, Mikhalev A, Kaibysheva V, Atiakshin D, Motilev E, et al. Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis. Biomedicines 2023 Dec 1;11(12):3204. doi: 10.3390/biomedicines11123204

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

Baretton GB, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, et al. Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract. J Cancer Res Clin Oncol 2023 Nov;149(17):16231-16238. doi: 10.1007/s00432-023-05180-5. Epub 2023 Oct 24

Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes

Clausen S, Falk M, Oesterling F, Fehr A, Stang A, Boecker W, et al. Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes. Anticancer Res 2022 Mar;42(3):1455-1463. doi 10.21873/anticanres.15616

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Christopoulos P, Herster F, Hoffknecht P, Falk M, Tiemann M, Kopp HG, et al. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report. Front Oncol 2024 May 06;14:1347742. doi: 10.3389/fonc.2024.1347742

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Falk M, Schatz S, Reich FPM, Schmidt S, Galster M, Tiemann M, et al. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report. Curr. Oncol. 2023 Sep 28;30(10):8865-8871. doi:10.3390/curroncol30100640

Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab

Weimer J, Hüttmann M, Nusilati A, Andreas S, Röseler J, Tribian N, et al. Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non‐invasive vaginal swab. J Cell Mol Med. 2023 Jan 10;27(3):379-391. doi:10.1111/jcmm.17658

Pharmacological and physiological assessment of serotonin formation and degradation in isolated preparations from mouse and human hearts

Gergs U, Jung F, Buchwalow IB, Hofmann B, Simm A, Treede H, Neumann J. Pharmacological and physiological assessment of serotonin formation and degradation in isolated preparations from mouse and human hearts. Am J Physiol Heart Circ Physiol 2017 Dec 1;313(6):H1087-H1097. doi:10.1152/ajpheart.00350.2017

Castleman’s disease in the rheumatological practice

Schmalzing M, Sander O, Seidl M, et al. Castleman’s disease in the rheumatological practice. Z Rheumatol 2024 Aug 22;83(3). doi:10.1007/s00393-024-01560-5

Signaling Pathways in the Pathogenesis of Barrett’s Esophagus and Esophageal Adenocarcinoma

Maslenkina K, et al. Signaling Pathways in the Pathogenesis of Barrett’s Esophagus and Esophageal Adenocarcinoma. Int J Mol Sci 2023 May 26;24(11):9304. doi:10.3390/ijms24119304

Mast Cells in Regeneration of the Skin in Burn Wound with Special Emphasis on Molecular Hydrogen Effect

Atiakshin D, et al. Mast Cells in Regeneration of the Skin in Burn Wound with Special Emphasis on Molecular Hydrogen Effect. Pharmaceuticals (Basel) 2023 Feb 24;16(3):348. doi:10.3390/ph16030348

The Remodeling of Dermal Collagen Fibrous Structures in Mice under Zero Gravity: The Role of Mast Cells

Shishkina V, et al. The Remodeling of Dermal Collagen Fibrous Structures in Mice under Zero Gravity: The Role of Mast Cells. Int J Mol Sci 2023; Jan 18;24(3):1939. doi: 10.3390/ijms24031939

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy

Falk M, et al. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Curr Oncol 2023 Jan 30;30(2):1692-1698. doi:10.3390/curroncol30020130

Genetic alterations affecting the C-terminus of cyclin D1 are recurrent events in mantle cell lymphoma

Laccarino I, et al. Genetic alterations affecting the C-terminus of cyclin D1 are recurrent events in mantle cell lymphoma. Histopathology 2023 Jan;82(2):371-373. doi:10.1111/his.14815. Epub 2022 Oct 13

A Formylglycine-Peptide for the Site-Directed Identification of Phosphotyrosine-Mimetic Fragments

Tiemann M, et al. A Formylglycine-Peptide for the Site-Directed Identification of Phosphotyrosine-Mimetic Fragments. Chemistry 2022 Oct 12;28(57):e202201282. doi:10.1002/chem.202201282

Recent Advances in Castleman Disease

Hoffmann C, et al. Recent Advances in Castleman Disease. Oncol Res Treat 2022;45(11):693-704. doi:10.1159/000526640. Epub 2022 Oct 11

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Jori B, et al. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Current Oncol 2022 Sep 16;29(9):6628-6634. doi:10.3390/curroncol29090520

Protease Profile of Tumor-Associated Mast Cells in Melanoma

Atiakshin D, et al. Protease Profile of Tumor-Associated Mast Cells in Melanoma. Int J Mol Sci 2022 Aug 11;23(16):8930. doi:10.3390/ijms23168930

Pentafluorophosphato-Phenylalanines: Amphiphilic Phosphotyrosine Mimetics Displaying Fluorine-Specific Protein Interactions

Accorsi M, et al. Pentafluorophosphato-Phenylalanines: Amphiphilic Phosphotyrosine Mimetics Displaying Fluorine-Specific Protein Interactions. Angew Chem Int Ed Engl 2022 Jun 20;61(25):e202203579. doi:10.1002/anie.202203579

Atrial Giant Cell Myocarditis as a Cause of Heart Failure: Diagnostic Pathway and Successful Treatment

Paitazoglou C, Bergmann MW, Tiemann K, et al. Atrial Giant Cell Myocarditis as a Cause of Heart Failure: Diagnostic Pathway and Successful Treatment. JACC Case Rep. 2022 Jan 5;4(1):66-71. doi:10.1016/j.jaccas.2021.11.007

Carboxypeptidase A3-A Key Component of the Protease Phenotype of Mast Cells

Atiakshin D, et al. Carboxypeptidase A3-A Key Component of the Protease Phenotype of Mast Cells. Cells 2022 Feb 6;11(3):570. doi:10.3390/cells11030570

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Roeper J, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 2022 Jan;11(1):4-13. doi:10.21037/tlcr-21-754

Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping

Fehr A, et al. Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. Virchows Arch 2021 Nov;479(5):975-985. doi:10.1007/s00428-021-03146-x

MSI testing : What’s new? What should be considered?

MSI testing : What’s new? What should be considered? Pathologe 2021 Nov;42(Suppl 1):110-118. doi:10.1007/s00292-021-00948-3

Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples

Kuempers C, et al. Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples. Front Med 2021 Oct 8;8:734901. doi:10.3389/fmed.2021.734901. eCollection 2021

Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours

Brinker TJ, et al. Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. Eur J Cancer 2021 Sep;154:227-234. doi:10.1016/j.ejca.2021.05.026.

Expression of CD38 in Mast Cells: Cytological and Histotopographic Features

Atiakshin D, et al. Expression of CD38 in Mast Cells: Cytological and Histotopographic Features. Cells 2021 Sep 22;10(10):2511. doi:10.3390/cells10102511

Mechanisms of Systolic Cardiac Dysfunction in PP2A, PP5 and PP2AxPP5 Double Transgenic Mice

Dörner MF, et al. Mechanisms of Systolic Cardiac Dysfunction in PP2A, PP5 and PP2AxPP5 Double Transgenic Mice. Int J Mol Sci 2021 Aug 31;22(17). DOI:10.3390/ijms22179448

Comparison of Resistance Spectra After First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

Jori B et al. Comparison of Resistance Spectra After First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers 2021; Jun 8;13(12):2861. doi: 10.3390/cancers13122861.

Combined histochemical approach in assessing tryptase expression in the mast cell population

Atiakshin D, et al. Combined histochemical approach in assessing tryptase expression in the mast cell population. Acta Histochem 2021  May;123(4):151711. doi: 10.1016/j.acthis.2021.151711

Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis

Atiakshin D, et al. Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis. Histochem Cell Biol 2021 May;155(5):561-580. doi: 10.1007/s00418-021-01964-3

Histamine can be Formed and Degraded in the Human and Mouse Heart

Neumann J, et al. Histamine can be Formed and Degraded in the Human and Mouse Heart. Front Pharmacol 2021 May 11. doi.org/10.3389/fphar.2021.582916

Identification of CTLA-4-Positive Cells in the Human Tonsil

Tiemann M, et al. Identification of CTLA-4-Positive Cells in the Human Tonsil. Cells 2021 Apr 27;10(5):1027. doi: 10.3390/cells10051027

Protein Phosphatase 2A Improves Cardiac Functional Response to Ischemia and Sepsis

Gergs U, et al. Protein Phosphatase 2A Improves Cardiac Functional Response to Ischemia and Sepsis. Int J Mol Sci 2021 Apr 23;23(9):4688. doi.org/10.3390/ijms23094688

Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor–Immune Interactions

Lipinski S, Tiemann K, Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor–Immune Interactions. Int J Mol Sci 2021 Apr;22(7): 3374. doi: 10.3390/ijms22073374

Twenty-Eight Cases of Extraocular Sebaceous Carcinoma: A Correlative Clinicopathological and Immunohistochemical Analysis of Extraocular Sebaceous Carcinomas and Benign Sebaceous Gland Tumors.

Boecker W, et al. Twenty-Eight Cases of Extraocular Sebaceous Carcinoma: A Correlative Clinicopathological and Immunohistochemical Analysis of Extraocular Sebaceous Carcinomas and Benign Sebaceous Gland Tumors. Am J Dermatopathol 2021 Feb 1;43(2):93-102. doi: 10.1097/DAD.0000000000001667

Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study

Schmitt M, et al .Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. J Med Internet Res 2021 Feb 2;23(2):e23436. doi: 10.2196/23436

TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib

Roeper J, et al. TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib. Transl Lung Cancer Res 2021 Jan;11(1):4-13. doi: 10.21037/tlcr-21-754

Initial Characterization of Stressed Transgenic Mice With Cardiomyocyte-Specific Overexpression of Protein Phosphatase 2C

Bollmann P, et al. Initial Characterization of Stressed Transgenic Mice With Cardiomyocyte-Specific Overexpression of Protein Phosphatase 2C. Front Pharmacol 2021 Jan 11;11:591773. DOI: 10.3389/fphar.2020.591773

Initial Characterization of Transgenic Mice Overexpressing Human Histamine H2 Receptors

Gergs U, Bernhardt G, Buchwalow IB, Edler H, Fröba J, Keller M, et al. Initial Characterization of Transgenic Mice Overexpressing Human Histamine H2 Receptors. J Pharmacol Exp Ther 2019 Apr;369(1):129-141. doi:10.1124/jpet.118.255711

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

Willing EM, Vollbrecht C, Vössing C, et al. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers 2023 Jun 30;15(13):3445. doi:10.3390/cancers15133445

Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective

Malapelle U, Tiseo M, Vivancos A, Kapp J, Serrano MJ, Tiemann M. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. J. Mol. Pathol. 2021 Aug 18;2(3):255-273. doi:10.3390/jmp2030022

Morbus Castleman – ein seltenes, heterogenes Krankheitsbild

Hoffmann C, Tepel J, Tiemann M. Morbus Castleman – ein seltenes, heterogenes Krankheitsbild. Best Practice Onkologie 2021 Mar 09;16:198-206. doi:10.1007/s11654-021-00300-4

BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy

Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, et al. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. Eur J Cancer 2021 May; DOI: 10.1016/j.ejca.2021.02.036

Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials

Reinartz G, et al. Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials. Oncologist 2020 May;25(5):e816-e832. doi: 10.1634/theoncologist.2019-0783

Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol

Haentschel M, et al. Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. Diagnostics (Basel) 2020 Jul 6;10(7):459. doi: 10.3390/diagnostics10070459

Biological Characterization, Mechanistic Investigation and Structure-Activity Relationships of Chemically Stable TLR2 Antagonists

Bermudez M, et al. Biological Characterization, Mechanistic Investigation and Structure-Activity Relationships of Chemically Stable TLR2 Antagonists. ChemMedChem 2020 Jul 20;15(14):1364-1371. doi: 10.1002/cmdc.202000060

Signal amplification in immunohistochemistry: loose-jointed deformable heteropolymeric HRP conjugates vs. linear polymer backbone HRP conjugates

Buchwalow I, et al. Signal amplification in immunohistochemistry: loose-jointed deformable heteropolymeric HRP conjugates vs. linear polymer backbone HRP conjugates. Acta Histochem 2013 Jul;115(6):587-94. doi:10.1016/j.acthis.2012.12.008

EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®)

Petersen I, et al. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®). Pathol Res Pract 2017 Sept;213(12). doi: 10.1016/j.prp.2017.09.021

Mast cells and collagen fibrillogenesis

Atiakshin D, et al. Mast cells and collagen fibrillogenesis. Histochem Cell Biol 2020 Jul;154(1):21-40. DOI: 10.1007/s00418-020-01875-9

Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast

Boecker W, et al. Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast. Virchows Arch 2017 May;470(5):493-504. doi:10.1007/s00428-017-2073-7

Therapiestandards und Perspektiven beim nichtkleinzelligen Lungenkarzinom im Stadium IV

Reck M, et al. Therapiestandards und Perspektiven beim nichtkleinzelligen Lungenkarzinom im Stadium IV. Onkologie 2012; 35(Suppl 3):10–13. doi:10.1159/000338986

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

Tiemann M, et al. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Res Notes 2020 Mar 7;13(1):139. DOI: 10.1186/s13104-020-04975-w

Characterization of mast cell populations using different methods for their identification

Atiakshin D, et al. Characterization of mast cell populations using different methods for their identification. Histochem Cell Biol 2017 Jun;147(6):683-694. doi: 10.1007/s00418-017-1547-7

Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma

Buchwalow I, et al. Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. Histochem Cell Biol 2017 Jun;147(6):683-694. doi:10.1007/s00418-017-1547-7

The contribution of Paul Ehrlich to histochemistry: a tribute on the occasion of the centenary of his death

Buchwalow I, et al. The contribution of Paul Ehrlich to histochemistry: a tribute on the occasion of the centenary of his death. Virchows Arch 2015 Jan;466(1):111-6. doi:10.1007/s00428-014-1677-4

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Berger LA, et al. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. J Thorac Oncol 2018 Dec;13(12):e243-e246. doi:10.1016/j.jtho.2018.08.2025 I2

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

Keppens C, et al. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018 Jul;20(4):483-494. doi:10.1016/j.jmoldx.2018.03.006

Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns

Hallas C, et al. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns. Leuk Res 2019 Jan;76:107-111. doi:10.1016/j.leukres.2018.10.003

Multiple immunolabeling with antibodies from the same host species in combination with tyramide signal amplification

Buchwalow I, Samoilova V, Boecker W, Tiemann M. Multiple immunolabeling with antibodies from the same host species in combination with tyramide signal amplification. Acta Histochem 2018 Jul;120(5):405-411. doi:10.1016/j.acthis.2018.05.002

Spatial analysis of p63, K5 and K7 defines two groups of progenitor cells that differentially contribute to the maintenance of normal sebaceous glands, extraocular sebaceous carcinoma and benign sebaceous tumors

Boecker W, et al. Spatial analysis of p63, K5 and K7 defines two groups of progenitor cells that differentially contribute to the maintenance of normal sebaceous glands, extraocular sebaceous carcinoma and benign sebaceous tumors. J Dermatol 2019 Mar;46(3):249-258. doi:10.1111/1346-8138.14765

Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)

Reinartz G, et al. Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL). Strahlenther Onkol 2019 Jun;195(6):544-557. doi:10.1007/s00066-019-01446-5

Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study

Stenzinger A, et al. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol 2020 Jul;15(7):1177-1189. DOI: 10.1016/j.jtho.2020.01.023

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH, et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018 Feb;72(3):449-459. doi: 10.1111/his.13375

Tryptase as a polyfunctional component of mast cells

Atiakshin D, et al. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol 2018 May;149(5):461-477. doi: 10.1007/s00418-018-1659-8

Mast cell chymase: morphofunctional characteristics

Atiakshin D, et al. Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol 2019 Oct;152(4):253-269. DOI: 10.1007/s00418-019-01803-6

Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent

Boecker W, et al. Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent. Pancreas 2020 May/Jun 2020;49(5):683-691. doi: 10.1097/MPA.0000000000001548

One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group

Schem C, et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch 2009 Feb;454(2):203-10. doi:10.1007/s00428-008-0703-9

Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q

Tiemann K, et al. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol 2007 Sep;20(9):955-60. doi:10.1038/modpathol.3800902

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer–results from the GeparQuattro study (GBG 40)

Minckwitz G, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer–results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011 Apr;132(3):863-70. doi:10.1007/s10549-011-1621-0

Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation

Tiemann K, et al . Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation. Mod Pathol 2006 Nov;19(11):1409-13. doi:10.1038/modpathol.3800664

Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis

Sipos B, et al. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol 2005 Nov;207(3):301-12. doi:10.1002/path.1840

Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer

Maass N, et al. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Clinical Trial 2014; 87(5):300-10. doi:10.1159/000365553. Epub 2014 Aug 26

Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells

Boecker W, et al. Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells. Virchows Arch 2015 Jan;466(1):21-36. doi:10.1007/s00428-014-1671-x. Epub 2014 Oct 26

K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation

Boecker W, et al. K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation. Mod Pathol 2013 Aug;26(8):1086-100. doi:10.1038/modpathol.2013.45

BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia

Hallas C, et al. BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia. BMC Cancer 2016 Aug 18;16:648. doi:10.1186/s12885-016-2707-1

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Loibl S, et al. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res 2016 Jun 1;22(11):2675-83. doi:10.1158/1078-0432.CCR-15-0965

Oxidative stress and NO generation in the rat pancreatitis induced by pancreatic duct ligation

Buchwalow I, et al. Oxidative stress and NO generation in the rat pancreatitis induced by pancreatic duct ligation. Acta Histochem 2017 Apr;119(3):252-256. doi:10.1016/j.acthis.2017.01.010

L-arginine-NO-cGMP signalling pathway in pancreatitis

Buchwalow I, et al. L-arginine-NO-cGMP signalling pathway in pancreatitis. Sci Rep 2013;3:1899. doi:10.1038/srep01899

Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept

Boecker W, et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept. Histochem Cell Biol 2020 Jul;154(1):97-105. doi: 10.1007/s00418-020-01864-y

Immunohistochemical and molecular profile of salivary gland cancer in children

Locati LD, et al. Immunohistochemical and molecular profile of salivary gland cancer in children. Pediatr Blood Cancer 2017 Sep;64(9). doi: 10.1002/pbc.26468

Spatially correlated phenotyping reveals K5-positive luminal progenitor cells and p63-K5/14-positive stem cell-like cells in human breast epithelium

Boecker W, et al. Spatially correlated phenotyping reveals K5-positive luminal progenitor cells and p63-K5/14-positive stem cell-like cells in human breast epithelium. Lab Invest 2018 Aug;98(8):1065-1075. doi: 10.1038/s41374-018-0054-3

New Insight into the Role of Nitric Oxide Pathways in Pancreas

Buchwalow IB, et al. New Insight into the Role of Nitric Oxide Pathways in Pancreas. Acta Histochem Cytochem 2018 Dec 20;51(6):167-172. doi: 10.1267/ahc.1802

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Michels S, et al. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016 Jan;11(1):122-7. doi:10.1016/j.jtho.2015.09.016

A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay

Menon R, et al. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. J Thorac Oncol 2016 Sep;11(9):e105-7. doi:10.1016/j.jtho.2016.04.005

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Ortiz-Cuaran S, et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Canc Res 2016 Oct 1;22(19):4837-4847. doi:10.1158/1078-0432.CCR-15-1915

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Scheel AH, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016 Oct;29(10):1165-72. doi:10.1038/modpathol.2016.117

Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer

Latteyer S, et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 2016 Dec;54(3):733-741. doi:10.1007/s12020-016-1080-9

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models

Pajtler KW, et al. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget 2017 Jan 24;8(4):6730-6741. doi:10.18632/oncotarget.14268

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

Michels S, et al. ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. NPJ Precis Oncol 2017 Mar 20;1(1):4. doi:10.1038/s41698-017-0004-3

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status

Gottlieb A, et al. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget 2017 Apr 25;8(17):27882-27891. doi:10.18632/oncotarget.15840

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens

Müller J, et al. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol 2017 Oct;12(10):1503-1511. doi:10.1016/j.jtho.2017.07.014

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

Brägelmann J, et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep 2017 Sep 19;20(12):2833-2845. doi:10.1016/j.celrep.2017.08.082

Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing

Christopoulos P, et al. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

Schatz S, et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers 2020 Jun 24;12(6):1685. doi: 10.3390/cancers12061685

Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary

Bochtler T, et al. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.  Int J Cancer 2020 Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Wagener-Ryczek S, et al. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer 2020 May 12;20(1):408. doi: 10.1186/s12885-020-06920-3

Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC

Volz C, et al. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep 2020 Apr 28;31(4):107568. doi: 10.1016/j.celrep.2020.107568

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

Roeper J, et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.  Oncotarget 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen E, et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

Michels S, et al. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precis Oncol 2019 Mar 27;3. doi: 10.1200/PO.18.00210

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Michels S, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, et al. Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)

Frank R, et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Canc Res 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Plenker D, et al. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin Canc Res 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy

Lakis S, Heukamp LC, Griesinger F. Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. J Thorac Oncol 2017 Nov;12(11):e186-e188. doi:10.1016/j.jtho.2017.07.018

to top icon